Literature DB >> 24706216

Dose adjustment of carboplatin in patients on peritoneal dialysis.

Achuta K Guddati1, Parijat S Joy, Creticus P Marak.   

Abstract

The Calvert equation has been extensively used to determine the dosage of carboplatin. However, in patients on dialysis, it predicts the same dosage regardless of the frequency of dialysis. Clearance of carboplatin during hemodialysis has been studied to a lesser extent, but there have been very few studies which have investigated the clearance of carboplatin in patients on peritoneal dialysis. A mathematical formula is proposed here to predict the dose of carboplatin for a given AUC in patients on peritoneal dialysis. This formula takes into account the frequency of dialysis sessions and the time delay between carboplatin infusion and the initiation of dialysis. The formula predicts an approximately similar dosage of carboplatin as that of the Calvert formula in patients undergoing peritoneal dialysis four times per day if dialysis is initiated 12 h after infusion. The formula may help in guiding the adjustment of carboplatin dose in patients who receive a lesser number of dialysis sessions per day and in those patients whose dialysis is initiated at different times (0-24 h) after carboplatin infusion. It is suggested that usage of this formula will result in a better dosage of carboplatin to suit specific dialysis frequencies in specific patients and eventually may result in a better efficacy and toxicity profile.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24706216     DOI: 10.1007/s12032-014-0946-z

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  5 in total

1.  Dose adjustment of carboplatin in patients on hemodialysis.

Authors:  Achuta K Guddati; Parijat S Joy; Creticus P Marak
Journal:  Med Oncol       Date:  2014-01-23       Impact factor: 3.064

2.  ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends.

Authors:  Aileen Grassmann; Simona Gioberge; Stefan Moeller; Gail Brown
Journal:  Nephrol Dial Transplant       Date:  2005-10-04       Impact factor: 5.992

3.  Cancer in patients on dialysis for end-stage renal disease: an international collaborative study.

Authors:  P Maisonneuve; L Agodoa; R Gellert; J H Stewart; G Buccianti; A B Lowenfels; R A Wolfe; E Jones; A P Disney; D Briggs; M McCredie; P Boyle
Journal:  Lancet       Date:  1999-07-10       Impact factor: 79.321

4.  Continuous ambulatory peritoneal dialysis: pharmacokinetics and clinical outcome of paclitaxel and carboplatin treatment.

Authors:  Joan B Heijns; Maria E L van der Burg; Teun van Gelder; Marien W J A Fieren; Peter de Bruijn; Ate van der Gaast; Walter J Loos
Journal:  Cancer Chemother Pharmacol       Date:  2008-01-19       Impact factor: 3.333

5.  Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

Authors:  A H Calvert; D R Newell; L A Gumbrell; S O'Reilly; M Burnell; F E Boxall; Z H Siddik; I R Judson; M E Gore; E Wiltshaw
Journal:  J Clin Oncol       Date:  1989-11       Impact factor: 44.544

  5 in total
  1 in total

1.  Case Report: Safety and Efficacy of Enfortumab Vedotin in a Patient With Metastatic Urothelial Carcinoma Undergoing Peritoneal Dialysis.

Authors:  Kaylyn R Collette; Zin W Myint; Saurabh V Parasramka; Carleton S Ellis
Journal:  Front Oncol       Date:  2022-05-25       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.